undamentalytics Newsletter
Sign in

Indivior Pharmaceuticals, Inc. revenue

Indivior Pharmaceuticals, Inc.'s revenue was $1.24bn in fiscal 2025, up 4.3% on the year before. Since fiscal 2022 ($901m) it has grown at a compound 11.2% a year. Over the last twelve months it was $1.37bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue9011,0931,1881,2391,374
Growth on the year before—+21.3%+8.7%+4.3%—
Gross profit7499199579941,168
Gross margin83.1%84.1%80.6%80.2%85.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Indivior Pharmaceuticals, Inc. $1.37bn 16.3% —
Phibro Animal Health Corp $1.52bn 17.1% 15.8%
Lantheus Holdings, Inc. $1.56bn 2.3% 11.4%
Trulieve Cannabis Corp. $1.14bn -3.9% -0.6%
Prestige Consumer Healthcare Inc. $1.10bn -1.4% -0.7%
ANI Pharmaceuticals Inc $978m 30.9% 34.6%

Compare with peers

Head to head: INDV vs PAHCINDV vs LNTHINDV vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Indivior Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Indivior Pharmaceuticals, Inc.